Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Thomas Budd

Showing results (31-40 of 103) with videos related to

Pageof 11
Sort By:
Oncotarget|December 29, 2011
Phosphatase inhibitor, sodium stibogluconate, in combination with interferon (IFN) alpha 2b: phase I trials to identify pharmacodynamic and clinical effectsTaolin Yi, Paul Elson, Masato Mitsuhashi, et al.
Scientific Reports|February 18, 2017
Palindromic amplification of the ERBB2 oncogene in primary HER2-positive breast tumorsMichael Marotta, Taku Onodera, Jeffrey Johnson, et al.
Investigational New Drugs|November 27, 2002
Biochemical modulation of 5-fluorouacil through dihydropyrimidine dehydrogenase inhibition: a Southwest Oncology Group phase II trial of eniluracil and 5-fluorouracil in advanced resistant colorectal cancerCynthia G Leichman, Kari Chansky, John S Macdonald, et al.
International Journal of Fertility and Women'S Medicine|February 3, 2007
HER2 status in bilateral breast cancerJoseph P Crowe, Rebecca J Patrick, Lisa A Rybicki, et al.
BMC Cancer|September 1, 2016
MET and PTEN gene copy numbers and Ki-67 protein expression associate with pathologic complete response in ERBB2-positive breast carcinoma patients treated with neoadjuvant trastuzumab-based therapyBenjamin C Calhoun, Bryce Portier, Zhen Wang, et al.
Cancer|December 20, 2002
Phase I trial of weekly docetaxel and gemcitabine in patients with refractory malignanciesTarek Mekhail, Thomas E Hutson, Paul Elson, et al.
Oncotarget|October 5, 2013
HER4 expression status correlates with improved outcome in both neoadjuvant and adjuvant Trastuzumab treated invasive breast carcinomaBryce P Portier, Eugen C Minca, Zhen Wang, et al.
Breast Cancer Research : BCR|November 28, 2012
A common copy-number breakpoint of ERBB2 amplification in breast cancer colocalizes with a complex block of segmental duplicationsMichael Marotta, Xiongfong Chen, Ayako Inoshita, et al.
Anticancer Research|March 25, 2010
Phase II clinical trial of imatinib mesylate in therapy of KIT and/or PDGFRalpha-expressing Ewing sarcoma family of tumors and desmoplastic small round cell tumorsJoseph Chao, G Thomas Budd, Peiguo Chu, et al.
Breast Cancer Research and Treatment|April 12, 2011
Specific kinesin expression profiles associated with taxane resistance in basal-like breast cancerMin Han Tan, Sarmishtha De, Gurkan Bebek, et al.
Pageof 11

Showing results (31-40 of 103) with videos related to

Sort By:
Pageof 11
Oncotarget|December 29, 2011
Phosphatase inhibitor, sodium stibogluconate, in combination with interferon (IFN) alpha 2b: phase I trials to identify pharmacodynamic and clinical effectsTaolin Yi, Paul Elson, Masato Mitsuhashi, et al.
Scientific Reports|February 18, 2017
Palindromic amplification of the ERBB2 oncogene in primary HER2-positive breast tumorsMichael Marotta, Taku Onodera, Jeffrey Johnson, et al.
Investigational New Drugs|November 27, 2002
Biochemical modulation of 5-fluorouacil through dihydropyrimidine dehydrogenase inhibition: a Southwest Oncology Group phase II trial of eniluracil and 5-fluorouracil in advanced resistant colorectal cancerCynthia G Leichman, Kari Chansky, John S Macdonald, et al.
International Journal of Fertility and Women'S Medicine|February 3, 2007
HER2 status in bilateral breast cancerJoseph P Crowe, Rebecca J Patrick, Lisa A Rybicki, et al.
BMC Cancer|September 1, 2016
MET and PTEN gene copy numbers and Ki-67 protein expression associate with pathologic complete response in ERBB2-positive breast carcinoma patients treated with neoadjuvant trastuzumab-based therapyBenjamin C Calhoun, Bryce Portier, Zhen Wang, et al.
Cancer|December 20, 2002
Phase I trial of weekly docetaxel and gemcitabine in patients with refractory malignanciesTarek Mekhail, Thomas E Hutson, Paul Elson, et al.
Oncotarget|October 5, 2013
HER4 expression status correlates with improved outcome in both neoadjuvant and adjuvant Trastuzumab treated invasive breast carcinomaBryce P Portier, Eugen C Minca, Zhen Wang, et al.
Breast Cancer Research : BCR|November 28, 2012
A common copy-number breakpoint of ERBB2 amplification in breast cancer colocalizes with a complex block of segmental duplicationsMichael Marotta, Xiongfong Chen, Ayako Inoshita, et al.
Anticancer Research|March 25, 2010
Phase II clinical trial of imatinib mesylate in therapy of KIT and/or PDGFRalpha-expressing Ewing sarcoma family of tumors and desmoplastic small round cell tumorsJoseph Chao, G Thomas Budd, Peiguo Chu, et al.
Breast Cancer Research and Treatment|April 12, 2011
Specific kinesin expression profiles associated with taxane resistance in basal-like breast cancerMin Han Tan, Sarmishtha De, Gurkan Bebek, et al.
Pageof 11